Outcomes of On-Label Reduced-Dose Edoxaban in Patients With Atrial Fibrillation: The LEDIOS Registry

BACKGROUND: Non-vitamin K antagonist oral anticoagulants (NOACs) are effective in preventing thromboembolisms and reduce the risk of bleeding compared with warfarin. There are few reports on the outcomes of on-label reduced-dose NOACs. The aim of this study was to assess the safety and efficacy of o...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Ju Youn, Choi, Eue Keun, Lim, Hong Euy, Oh, Yong-Seog, Cho, Youngjin, On, Young Keun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Medical Sciences 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745682/
https://www.ncbi.nlm.nih.gov/pubmed/36513051
http://dx.doi.org/10.3346/jkms.2022.37.e335

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745682/
https://www.ncbi.nlm.nih.gov/pubmed/36513051
http://dx.doi.org/10.3346/jkms.2022.37.e335

Ejemplares similares